Cost Pressures Prompt Possible Fee Increases In Australia
Regulator Proposes Potentially Slower Drug Reviews Or Higher Fees
Executive Summary
The Australian regulator, the TGA, is having to deal with increased cost pressures stemming from a rise in applications for unauthorized drugs, including medicinal cannabis.